Status:
COMPLETED
Observational Study of ALNA® (Tamsulosin) in Patients With Benign Prostatic Hyperplasia (BPH)
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Prostatic Hyperplasia
Eligibility:
MALE
Brief Summary
The objectives of this post marketing surveillance study were to document the comorbidity and comedication during prescription of ALNA® (Tamsulosin) for patients with BPH (Benign Prostatic Hyperplasia...
Eligibility Criteria
Inclusion
- Indication for the treatment with ALNA according to its summary of product characteristics (SPC)
Exclusion
- Patients fulfilling one of the general or specific contraindications listed in the ALNA SPC, particularly patients with known hypersensitivities against tamsulosin hydrochloride or any other ingredient of the product, orthostatic dysregulation or severe liver insufficiency cannot be included in the study
Key Trial Info
Start Date :
May 1 2003
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
7391 Patients enrolled
Trial Details
Trial ID
NCT02245503
Start Date
May 1 2003
Last Update
September 19 2014
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.